Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.

Co-located with our

REAL WORLD EVIDENCE SUMMIT

2018 Conference Agenda

7:30
-
8:30
REGISTRATION
8:30
-
8:35
WELCOME FROM ORGANIZER
Opening Keynote Session
8:35
-
9:05
Patient Engagement at a pharmaceutical company – Case studies at UCB Japan
  • History of “Patient Centricity” at UCB Japan
  • Evolution from “Patient Centricity” to “Patient Value Strategy” as UCB’s Global Strategy
  • Case studies at UCB Japan: a patient value mind-set at all levels of the organisation – current challenges and future

UCB Japan Co., Ltd. Satoshi Miki Japan Representative Director, Vice President, Head of CoE Strategy & Planning for East Asia Region UCB Japan Co., Ltd.

9:05
-
9:50
Overcome pricing challenges: ensure your model demonstrates and communicates your true product value
  • Prepare to show exactly how your product provides improved long-term value to the Japanese market in order to tackle the pricing challenges
  • Meet the requirements of upcoming healthcare policy, and find how you can help and support the Japanese healthcare system

Company_Name Ole Mølskov Bech President and Representative Director Novo Nordisk Pharma Ltd. Chairman EFPIA-Japan

Company_Name Thorsten Poehl President and Representative Director Boehringer Ingelheim Japan, Inc. Chairman and Representative Director Nippon Boehringer Ingelheim Co., Ltd.
Boehringer Ingelheim Animal Health Japan Co., Ltd.
Boehringer Ingelheim Seiyaku
Vice Chairman EFPIA-Japan

9:50
-
10:20
The Act on the Next-Generation Medical Infrastructure
  • To grasp the overview of "The Act on the Next-Generation Medical Infrastructure" promulgated for the realization of advanced and efficient medical care through the utilization of medical ICT.
  • To understand the impact of "The Act on the Next-Generation Medical Infrastructure" on research and business environment surrounding pharmaceutical companies.

Councillor, Cabinet Secretariat, Government of Japan Koji Fujimoto Deputy Director-General, Office of Healthcare Policy Councillor, Cabinet Secretariat, Government of Japan

10:20
-
11:05
COFFEE BREAK
Do you really know your customer?
Gain a deeper market understanding to predict customer behavior and determine where to add value
11:05
-
11:35
Should patients be treated as "customers"? Consider pharma's social responsibility
  • Should pharmaceutical companies treat patients as their "customers"?
  • The presenter will discuss the appropriateness of adapting the concept of "customer creation" to patients in light of the patient narratives in
  • DIPEx (Database of Individual Patient Experiences)

DIPEx-Japan Rika Sakuma Sato Managing Director
Approved Specified Nonprofit Organization
DIPEx-Japan

11:35
-
12:05
Pharma’s mission: ‘Rethink the service’ from customer (Doctor & Patients) perspective
  • Re-realize pharma’s current situation
  • Understand the value to connect with customers (patients)
  • How to connect with customers (patients)

Kan-i net Nobuyuki Suzuki President Kan-i net

12:15
-
13:00
WORKSHOP (CMIC & MILLIMAN)
13:00
-
14:05
LUNCH
Create a comprehensive database
Make better decisions and open more doors with more reliable customer data
14:05
-
14:35
Challenges for seamless utilization of diverse data sources in Japan
  • Importance of master data management to manage the abundant HCP related data compared to other countries.
  • How do we suppose the psychographics of HCP by utilizing touch point data in the past?
  • Preparation of analytical data mart to accelerate our cross channel analytics.

GlaxoSmithKline K.K. Yoshihiko Nakajima Head
MC Data & System Management
GlaxoSmithKline K.K.

14:35
-
15:05
Put information on patient-centered decision support between doctor and patients into a database
  • Encourage Patient-centered decision making
  • Learn the measuring method of shared decision making
  • Understand the effect of decision aid and it's international standard

St. Luke's International University Kazuhiro Nakayama Professor
Graduate school of nursing science
St. Luke's International University

15:05
-
15:35
Prediction of market share over time after launch using machine learning and real-world data, and its application
  • Introduce a theory of market share prediction using machine learning
  • Report results of back tests on example data of some launched products
  • Propose a method to design a PDCA cycle for marketing based on the share prediction

Milliman, Inc. Kosuke Iwasaki Director
Japan Healthcare Practice and Data Analytics
Milliman, Inc.

13:00
-
14:05
COFFEE BREAK
Enhance customer engagement through digital innovation
Determine which technologies will get you ahead
16:05
-
16:35
How will we manage digital ecosystem to drive patient
  • Make good use of pharma’s strength to understand patients
  • The appropriate way to connect with patients
  • Add value by combining other industry’s usual product and service to your digital strategy

Merck Ltd. Shinichiro Akaho Head of Business Technology Merck Ltd.

16:35
-
17:05
Perspectives for Digital expansion in Japan
  • Thinking Digital beyond marketing; the organization challenge
  • Thinking Digital beyond reaching doctors; the target challenge
  • Thinking Digital beyond Pharma: the paradigm shift challenge
  • Thinking Digital, Re-thinking healthcare: the challenge of a new Vision

Company_Name Philippe Auvaro Managing Director
Senior Managing Executive Officer
CMIC HOLDINGS Co., Ltd. President, Representative Director OrphanPacific, Inc.

17:05
-
17:50
PANEL DISCUSSION (SESSION 1A: Do you really know your customer?)
Collaboratively build partnership between pharma and patients
  • Listen to patients' hope & expectation and distrust & dissatisfaction towards pharma
  • How can patient organization and pharma build the right relationship
  • What patient organisation expect from patient organisation

JPPaC Kazuyoshi Hatanaka President Japan Partners for Patient-Centric Care (JPPaC)

DebRA Japan Keiko Miyamoto Representative Director DebRA Japan

Hokkaido Intractable Yasuko Masuda Executive Director General incorporated association
Hokkaido Intractable Diseases Association (Nanbyo –ren)

CanNet Makoto Kobayashi Executive Director (Tokyo office) CanNet

17:50
-
19:30
NETWORKING DRINKS
8:00
-
9:00
REGISTRATION
From mass-market to targeted
Improve your conversion rate with a more sophisticated approach
9:00
-
9:30
Effective safety information provision for the Future
  • Discuss the regulatory authority’s expectations on information provision (incl. safety information) by pharma and customer’s expectations on information provision
  • The effective way to collect/provide safety information under this future environment: Main channel to collect/provide safety information in the past was MR, however currently multiple channels are being developed by Medical and Marketing departments

Eli Lilly Japan K.K. Souta Mizumoto Director
Global Patient Safety, Quality and Patient Safety
Eli Lilly Japan K.K.

9:30
-
10:00
Next generation targeted sales and marketing utilizing customer big data
  • Key data that should be accumulated by pharmaceutical companies
  • Big data based optimization of resource allocations and of detail customization per physician
  • Digitalization of MR activities to facilitate big data accumulation and utilization, and the future of sales and marketing

M3, Inc. Yoichi Katayama Senior Director
Solution Partner Business Unit
M3, Inc.

10:00
-
10:30
Marketing plan: is it just a show? A discussion on how it should be put into practice
  • Mass quantitative analysis moves your sales people?
  • What is customer "insight"?
  • Tips for "realistic" marketing plan

Pola Pharma Inc. Hiroshi Horikawa General Manager
Marketing Department
Pola Pharma Inc.

10:30
-
11:00
COFFEE BREAK
Introduce smarter thinking into your sales force: go beyond simple sales techniques so that MRs become the customer representatives of the future
11:00
-
11:30
A focus on niche/speciality care sales techniques - understand how MRs should adapt
  • Shift towards' niche/speciality products which could potentially yield good profits
  • Create a personalized approach with a deeper understanding of your customer and a more sophisticated model

Aegerion Pharmaceuticals K.K. Masako Nakamura President, Representative Director Aegerion Pharmaceuticals K.K.

11:30
-
12:00
Build smarter thinking into your sales force: go beyond the usual MR model and think how it should change
  • Evaluate what should stay the same and should change, looking to current trends and future.
  • As the external environment becomes ever so complicated, how can the field staff and head office communicate well
  • Future tasks to optimize human productivity

Gilead Sciences K.K. Tomoo Miyake Associate Director
Sales Promotion/Learning Development Dept.
Gilead Sciences K.K.

12:00
-
13:15
LUNCH
Successfully execute your commercial strategy: Manage a forward looking transition
13:15
-
13:45
Walk before you run: how to map community-based healthcare and plan the best organizational structure
  • Identify how you can adapt to the different role of each stakeholder from this point onwards
  • Spot the vital signs in order to keep your ear close to market shifts
  • How to position your teams as strategic partners in improving Japanese healthcare

Celgene K.K. Satoru Noguchi President Celgene K.K.

Toho Holdings Co., Ltd. Hiroshi Ito General Manager
Regional Medical Cooperation Department
Toho Holdings Co., Ltd.

Shionogi & Co., Ltd. Harumi Shimazui Head of Regional Strategic Planning and Healthcare Relations Department
Human Healthcare Division
Shionogi & Co., Ltd.

13:45
-
14:15
Make the right investments for commercial innovation: Deliver value through reliable data insight and digital intervention
  • Overcoming challenges in Japan’s healthcare system, including innovation adoption, pricing, care and aging society by focusing on value and providing holistic solutions
  • Realizing meaningful customer experiences through data, digital and technology, global and local approaches
  • Partnering for long-term value in the Japanese healthcare system – what is pharma role?

Novartis David Lennon Oncology General Manager Japan Novartis

14:15
-
15:00
PANEL DISCUSSION:
Determine whether sales skills are the defining factor in the future MR - and whether certain parts of the role should now be automated for order to focus elsewhere
  • Enough discussion; let's clarify where to allocate your resources effectively for our new landscape
  • How to determine the right ratio of MRs for your company depending on capabilities required
  • Your 2020 vision: Which it be the same path for everyone, or are your requirements unique?

Aegerion Pharmaceuticals K.K. Masako Nakamura President, Representative Director Aegerion Pharmaceuticals K.K.

Gilead Sciences K.K. Tomoo Miyake Associate Director
Sales Promotion/Learning Development Dept.
Gilead Sciences K.K.

The Nielsen Company Japan Kazuhiro Miyatsu Executive Director
Marketing Science Analytics & Consulting
The Nielsen Company Japan

15:00
-
15:30
COFFEE BREAK
Closing Keynote Session
15:30
-
16:00
Healthcare transformation through medical big data platform and future role of pharmaceutical companies
  • Introduce case examples on data collection and analysis of medical big data platform in Japan and the U.S.
  • Discuss future roles of pharma companies in community health transformation and R&D innovation for new drug development

PwC Consulting LLC Yujiro Tsutsumi Managing Executive Director
Health Industries Advisory
PwC Consulting LLC

16:00
-
16:30
Get your talent formula right: optimize for effective leadership
  • Improving the work environment to boost business performance Purpose, inclusion and innovation
  • The era of internal collaboration: enabling co-operation across functions
  • Reward and recognition in for today's organizations

Novartis David Lennon Oncology General Manager Japan Novartis

EYEFORPHARMA JAPAN 2018 SPECIAL
-
PRESIDENT / CEO PANEL DISCUSSION
16:30
-
17:15
Pharma as the primary partner for improving Japanese healthcare
  • How our companies can form a new relationship with stakeholders and work on shared objectives to create the ideal patient model
  • Examples from other countries where similar partnerships have provided win-win-win-win situations for pharma, government, HCP and patients
  • Visualizations of Japanese healthcare in 2020 & 2025: How is your workforce going to change?

Company_Name Satoru Noguchi President Celgene K.K.

Company_Name Ole Mølskov Bech President and Representative Director Novo Nordisk Pharma Ltd. Chairman EFPIA-Japan

Company_Name Stefan Woxström Representative Director and President AstraZeneca K.K.

7:30
-
8:30
REGISTRATION
8:30
-
8:35
WELCOME FROM ORGANIZER
Opening Keynote Session
8:35
-
9:05
Patient Engagement at a pharmaceutical company – Case studies at UCB Japan
  • History of “Patient Centricity” at UCB Japan
  • Evolution from “Patient Centricity” to “Patient Value Strategy” as UCB’s Global Strategy
  • Case studies at UCB Japan: a patient value mind-set at all levels of the organisation – current challenges and future

UCB Japan Co., Ltd. Satoshi Miki Japan Representative Director, Vice President, Head of CoE Strategy & Planning for East Asia Region UCB Japan Co., Ltd.

9:05
-
9:50
Overcome pricing challenges: ensure your model demonstrates and communicates your true product value
  • Prepare to show exactly how your product provides improved long-term value to the Japanese market in order to tackle the pricing challenges
  • Meet the requirements of upcoming healthcare policy, and find how you can help and support the Japanese healthcare system

Company_Name Ole Mølskov Bech President and Representative Director Novo Nordisk Pharma Ltd. Chairman EFPIA-Japan

Company_Name Thorsten Poehl President and Representative Director Boehringer Ingelheim Japan, Inc. Chairman and Representative Director Nippon Boehringer Ingelheim Co., Ltd.
Boehringer Ingelheim Animal Health Japan Co., Ltd.
Boehringer Ingelheim Seiyaku
Vice Chairman EFPIA-Japan

9:50
-
10:20
The Act on the Next-Generation Medical Infrastructure
  • To grasp the overview of "The Act on the Next-Generation Medical Infrastructure" promulgated for the realization of advanced and efficient medical care through the utilization of medical ICT.
  • To understand the impact of "The Act on the Next-Generation Medical Infrastructure" on research and business environment surrounding pharmaceutical companies.

Councillor, Cabinet Secretariat, Government of Japan Koji Fujimoto Deputy Director-General, Office of Healthcare Policy Councillor, Cabinet Secretariat, Government of Japan

10:20
-
11:05
COFFEE BREAK
Do you really know your customer?
Gain a deeper market understanding to predict customer behavior and determine where to add value
11:05
-
11:35
Should patients be treated as "customers"? Consider pharma's social responsibility
  • Should pharmaceutical companies treat patients as their "customers"?
  • The presenter will discuss the appropriateness of adapting the concept of "customer creation" to patients in light of the patient narratives in
  • DIPEx (Database of Individual Patient Experiences)

DIPEx-Japan Rika Sakuma Sato Managing Director
Approved Specified Nonprofit Organization
DIPEx-Japan

11:35
-
12:05
Pharma’s mission: ‘Rethink the service’ from customer (Doctor & Patients) perspective
  • Re-realize pharma’s current situation
  • Understand the value to connect with customers (patients)
  • How to connect with customers (patients)

Kan-i net Nobuyuki Suzuki President Kan-i net

12:15
-
13:00
WORKSHOP (CMIC & MILLIMAN)
13:00
-
14:05
LUNCH
Create a comprehensive database
Make better decisions and open more doors with more reliable customer data
14:05
-
14:35
Challenges for seamless utilization of diverse data sources in Japan
  • Importance of master data management to manage the abundant HCP related data compared to other countries.
  • How do we suppose the psychographics of HCP by utilizing touch point data in the past?
  • Preparation of analytical data mart to accelerate our cross channel analytics.

GlaxoSmithKline K.K. Yoshihiko Nakajima Head
MC Data & System Management
GlaxoSmithKline K.K.

14:35
-
15:05
Put information on patient-centered decision support between doctor and patients into a database
  • Encourage Patient-centered decision making
  • Learn the measuring method of shared decision making
  • Understand the effect of decision aid and it's international standard

St. Luke's International University Kazuhiro Nakayama Professor
Graduate school of nursing science
St. Luke's International University

15:05
-
15:35
Prediction of market share over time after launch using machine learning and real-world data, and its application
  • Introduce a theory of market share prediction using machine learning
  • Report results of back tests on example data of some launched products
  • Propose a method to design a PDCA cycle for marketing based on the share prediction

Milliman, Inc. Kosuke Iwasaki Director
Japan Healthcare Practice and Data Analytics
Milliman, Inc.

13:00
-
14:05
COFFEE BREAK
Enhance customer engagement through digital innovation
Determine which technologies will get you ahead
16:05
-
16:35
How will we manage digital ecosystem to drive patient
  • Make good use of pharma’s strength to understand patients
  • The appropriate way to connect with patients
  • Add value by combining other industry’s usual product and service to your digital strategy

Merck Ltd. Shinichiro Akaho Head of Business Technology Merck Ltd.

16:35
-
17:05
Perspectives for Digital expansion in Japan
  • Thinking Digital beyond marketing; the organization challenge
  • Thinking Digital beyond reaching doctors; the target challenge
  • Thinking Digital beyond Pharma: the paradigm shift challenge
  • Thinking Digital, Re-thinking healthcare: the challenge of a new Vision

Company_Name Philippe Auvaro Managing Director
Senior Managing Executive Officer
CMIC HOLDINGS Co., Ltd. President, Representative Director OrphanPacific, Inc.

17:05
-
17:50
PANEL DISCUSSION (SESSION 1A: Do you really know your customer?)
Collaboratively build partnership between pharma and patients
  • Listen to patients' hope & expectation and distrust & dissatisfaction towards pharma
  • How can patient organization and pharma build the right relationship
  • What patient organisation expect from patient organisation

JPPaC Kazuyoshi Hatanaka President Japan Partners for Patient-Centric Care (JPPaC)

DebRA Japan Keiko Miyamoto Representative Director DebRA Japan

Hokkaido Intractable Yasuko Masuda Executive Director General incorporated association
Hokkaido Intractable Diseases Association (Nanbyo –ren)

CanNet Makoto Kobayashi Executive Director (Tokyo office) CanNet

17:50
-
19:30
NETWORKING DRINKS

Purchase the Post-Conference Materials

Event Presentations • Event Audio • On Demand Subscription

8:00
-
9:00
REGISTRATION
From mass-market to targeted
Improve your conversion rate with a more sophisticated approach
9:00
-
9:30
Effective safety information provision for the Future
  • Discuss the regulatory authority’s expectations on information provision (incl. safety information) by pharma and customer’s expectations on information provision
  • The effective way to collect/provide safety information under this future environment: Main channel to collect/provide safety information in the past was MR, however currently multiple channels are being developed by Medical and Marketing departments

Eli Lilly Japan K.K. Souta Mizumoto Director
Global Patient Safety, Quality and Patient Safety
Eli Lilly Japan K.K.

9:30
-
10:00
Next generation targeted sales and marketing utilizing customer big data
  • Key data that should be accumulated by pharmaceutical companies
  • Big data based optimization of resource allocations and of detail customization per physician
  • Digitalization of MR activities to facilitate big data accumulation and utilization, and the future of sales and marketing

M3, Inc. Yoichi Katayama Senior Director
Solution Partner Business Unit
M3, Inc.

10:00
-
10:30
Marketing plan: is it just a show? A discussion on how it should be put into practice
  • Mass quantitative analysis moves your sales people?
  • What is customer "insight"?
  • Tips for "realistic" marketing plan

Pola Pharma Inc. Hiroshi Horikawa General Manager
Marketing Department
Pola Pharma Inc.

10:30
-
11:00
COFFEE BREAK
Introduce smarter thinking into your sales force: go beyond simple sales techniques so that MRs become the customer representatives of the future
11:00
-
11:30
A focus on niche/speciality care sales techniques - understand how MRs should adapt
  • Shift towards' niche/speciality products which could potentially yield good profits
  • Create a personalized approach with a deeper understanding of your customer and a more sophisticated model

Aegerion Pharmaceuticals K.K. Masako Nakamura President, Representative Director Aegerion Pharmaceuticals K.K.

11:30
-
12:00
Build smarter thinking into your sales force: go beyond the usual MR model and think how it should change
  • Evaluate what should stay the same and should change, looking to current trends and future.
  • As the external environment becomes ever so complicated, how can the field staff and head office communicate well
  • Future tasks to optimize human productivity

Gilead Sciences K.K. Tomoo Miyake Associate Director
Sales Promotion/Learning Development Dept.
Gilead Sciences K.K.

12:00
-
13:15
LUNCH
Successfully execute your commercial strategy: Manage a forward looking transition
13:15
-
13:45
Walk before you run: how to map community-based healthcare and plan the best organizational structure
  • Identify how you can adapt to the different role of each stakeholder from this point onwards
  • Spot the vital signs in order to keep your ear close to market shifts
  • How to position your teams as strategic partners in improving Japanese healthcare

Celgene K.K. Satoru Noguchi President Celgene K.K.

Toho Holdings Co., Ltd. Hiroshi Ito General Manager
Regional Medical Cooperation Department
Toho Holdings Co., Ltd.

Shionogi & Co., Ltd. Harumi Shimazui Head of Regional Strategic Planning and Healthcare Relations Department
Human Healthcare Division
Shionogi & Co., Ltd.

13:45
-
14:15
Make the right investments for commercial innovation: Deliver value through reliable data insight and digital intervention
  • Overcoming challenges in Japan’s healthcare system, including innovation adoption, pricing, care and aging society by focusing on value and providing holistic solutions
  • Realizing meaningful customer experiences through data, digital and technology, global and local approaches
  • Partnering for long-term value in the Japanese healthcare system – what is pharma role?

Novartis David Lennon Oncology General Manager Japan Novartis

14:15
-
15:00
PANEL DISCUSSION:
Determine whether sales skills are the defining factor in the future MR - and whether certain parts of the role should now be automated for order to focus elsewhere
  • Enough discussion; let's clarify where to allocate your resources effectively for our new landscape
  • How to determine the right ratio of MRs for your company depending on capabilities required
  • Your 2020 vision: Which it be the same path for everyone, or are your requirements unique?

Aegerion Pharmaceuticals K.K. Masako Nakamura President, Representative Director Aegerion Pharmaceuticals K.K.

Gilead Sciences K.K. Tomoo Miyake Associate Director
Sales Promotion/Learning Development Dept.
Gilead Sciences K.K.

The Nielsen Company Japan Kazuhiro Miyatsu Executive Director
Marketing Science Analytics & Consulting
The Nielsen Company Japan

15:00
-
15:30
COFFEE BREAK
Closing Keynote Session
15:30
-
16:00
Healthcare transformation through medical big data platform and future role of pharmaceutical companies
  • Introduce case examples on data collection and analysis of medical big data platform in Japan and the U.S.
  • Discuss future roles of pharma companies in community health transformation and R&D innovation for new drug development

PwC Consulting LLC Yujiro Tsutsumi Managing Executive Director
Health Industries Advisory
PwC Consulting LLC

16:00
-
16:30
Get your talent formula right: optimize for effective leadership
  • Improving the work environment to boost business performance Purpose, inclusion and innovation
  • The era of internal collaboration: enabling co-operation across functions
  • Reward and recognition in for today's organizations

Novartis David Lennon Oncology General Manager Japan Novartis

EYEFORPHARMA JAPAN 2018 SPECIAL
-
PRESIDENT / CEO PANEL DISCUSSION
16:30
-
17:15
Pharma as the primary partner for improving Japanese healthcare
  • How our companies can form a new relationship with stakeholders and work on shared objectives to create the ideal patient model
  • Examples from other countries where similar partnerships have provided win-win-win-win situations for pharma, government, HCP and patients
  • Visualizations of Japanese healthcare in 2020 & 2025: How is your workforce going to change?

Company_Name Satoru Noguchi President Celgene K.K.

Company_Name Ole Mølskov Bech President and Representative Director Novo Nordisk Pharma Ltd. Chairman EFPIA-Japan

Company_Name Stefan Woxström Representative Director and President AstraZeneca K.K.

Purchase the Post-Conference Materials

Event Presentations • Event Audio • On Demand Subscription